Whilst targeting intracellular tau, rather than extracellular tau, may be a better therapeutic strategy for the treatment of Alzheimer’s disease, full-sized IgGs are ideal for targeting extracellular proteins such as the amyloid-β peptide that accumulates to form amyloid plaques in Alzheimer’s disease. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.